赵秀芳

[摘要] 目的 探討孟鲁司特钠联合卡介菌多糖核酸在儿科哮喘治疗中的应用效果。方法 纳入100例为方便选择自2014年1月—2017年5月期间的儿科哮喘患儿为研究对象；根据哮喘患儿的入院时间先后次序分为两组，对照组单一采用孟鲁司特钠治疗，研究组采用孟鲁司特钠联合卡介菌多糖核酸治疗；比较分析两组哮喘患儿的临床治疗效果及改善情况。结果 对照组治疗效果（72.00%）明显低于研究组（94.00%），差异有统计学意义（P<0.05）；对照组日间及夜间哮喘症状评分明显低于研究组，差异有统计学意义（P<0.05）；对照组治疗前的血清水平与研究组对比差异无统计学意义（P>0.05）；治疗后两组均有改善，而研究组改善幅度更大，差异有统计学意义（P<0.05）；对照组不良反应发生率（12.00%）明显高于研究组（2.00%），差异有统计学意义（P<0.05）。结论 在儿科哮喘治疗中给予哮喘患儿应用孟鲁司特钠联合卡介菌多糖核酸的临床应用效果显著，值得临床推广与应用。

[关键词] 哮喘；孟鲁司特钠；卡介茵多糖核酸；临床效果；哮喘症状评分

[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2018）01（a）-0128-03

Therapeutic Effect of Montelukast Combined with BCG Polysaccharide Nucleic Acid in the Treatment of Pediatric Asthma

ZHAO Xiu-fang

Pediatric Department， Tonghua Second Peoples Hospital， Tonghua， Jilin Province， 134003 China

[Abstract] Objective This paper tries to investigate the efficacy of Montelukast combined with BCG polysaccharide nucleic acid in the treatment of pediatric asthma. Methods A total of 100 children with pediatric asthma were conveniently selected from January 2014 to May 2017. The patients were divided into two groups according to the order of admission of asthma. The control group was treated with montelukast sodium alone. The combination of montelukast sodium combined with BCG polysaccharide nucleic acid treatment； comparative analysis of the two groups of children with asthma clinical treatment and improvement of the situation. Results The effect of treatment of the control group （72.00%） was significantly lower than that of the study group（94.00%）difference are statistically significant（P<0.05）； the control group day and night asthma symptom score was significantly lower than that of control groupdifference are statistically significant（P<0.05）； serum level and research group contrast group before treatment， there is no statistical significance in the difference（P>0.05）； the two groups after treatment were improved， and the study group improved more significantly， difference are statistically significant（P<0.05）； adverse reaction rate of the control group （12.00%） was significantly higher than that of the study group （2.00%）， difference are statistically significant（P<0.05）. Conclusion The clinical application of Montelukast Combined with BCG polysaccharide nucleic acid in the treatment of asthma in children is significant， and it is worthy of clinical promotion and application.

[Key words] Asthma； Montelukast sodium； Cardosine polysaccharide nucleic acid； Clinical effect； Asthma symptom score

哮喘是属于临床常见疾病，儿科哮喘好发于学龄前儿童，特别是3岁以下患儿[1]。目前临床给予儿科哮喘患儿以糖皮质激素吸入治疗为主要治疗手段，但是单一使用糖皮质激素的缺点较多，若未能够掌握吸药技术，则容易导致哮喘患儿出现咽部不适、声音嘶哑，部分患儿更会出现口腔溃疡或者口腔感染念珠菌等，导致临床治疗效果受影响，哮喘患儿治疗依从性及配合度低[2]。故此，如何选择有效控制哮喘发作的治疗方法是目前临床儿科医生亟需解决问题。该次研究工作特选取100例自2014年1月—2017年5月期間儿科收治入院的哮喘患儿为研究对象，旨在探讨观察并分析孟鲁司特钠联合卡介菌多糖核酸在儿科哮喘治疗中的应用效果，现报道如下。

1 资料与方法

1.1 一般资料